Strong Demand Has Thorne HealthTech (THRN) Poised For Continued Above-Market Growth Ahead

Thorne HealthTech (THRN) reported Q4 results last night. While net sales and adjusted earnings for the period of $63.0 million and 13 cents per share came in $1.1 million and 3 cents shy of their respective consensus estimates, this still marked a new record performance with continued fantastic year-over-year top-line growth of 27.7%. This came on the back of persistently strong demand across both its Direct-to-Consumer (DTC) and Professional/B2B channels, where sales rose 46.1% and 17.5% to $25.6 million and $37.3 million on increased order volume, subscription growth and an expanded network of healthcare professionals. And even with the sell-through of the higher-cost raw ingredients the company secured out of prudence (and to help maintain/expand market share) earlier in the year pressuring margins a bit more than anticipated, profits nearly doubled from the 7 cents earned last year.